Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

NCT05549258 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorder

Interventions

DRUG: Inebilizumab

Sponsor

Amgen